Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial
06:11am, Tuesday, 17'th Sep 2024
Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.
Buy 9 Sustainable Dividend Dogs From Barron's August 100
08:55am, Sunday, 15'th Sep 2024
Calvert Research and Management evaluated 1,000 large companies on 230 ESG indicators to rank the top 100 most sustainable companies for Barron's annual list. Nine dividend-paying ESG companies, inclu
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYN
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA in Combination With TACE Significantly Improved PFS Compared to TACE Alone in Patients With Unresectable, Non-Metastat
Where Will Merck Stock Be in 5 Years?
07:15am, Saturday, 14'th Sep 2024
Its blockbuster Keytruda cancer drug is scheduled to lose patent protection by the end of this decade. The company is betting on an extensive candidate pipeline and new indications to drive long-term
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA plus trastuzumab and chemotherapy OS results as first-line treatment in patients with HER2-positive advanced gastric or GEJ adenocarcinoma.
Merck Appears Ready To Return To June Highs (Technical Analysis)
01:31am, Saturday, 14'th Sep 2024
Merck's 15% decline in July is presenting investors with an intermediate to long-term buying opportunity. Long-term trend lines and Bollinger Bands indicate strong support at $110. We expect Merck to
Trade It or Fade It: The week's big biotech moves
06:52pm, Friday, 13'th Sep 2024
Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.
Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know
06:51pm, Friday, 13'th Sep 2024
In the most recent trading session, Merck (MRK) closed at $115.86, indicating a +0.53% shift from the previous trading day.
Here's Why Merck (MRK) Gained But Lagged the Market Today
06:56pm, Thursday, 12'th Sep 2024
Merck (MRK) closed at $115.25 in the latest trading session, marking a +0.47% move from the prior day.
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
11:16am, Tuesday, 10'th Sep 2024
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
12:50pm, Monday, 09'th Sep 2024
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
09:14am, Monday, 09'th Sep 2024
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck's
Sunday, Summit Therapeutics Inc. SMMT released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial
05:17am, Monday, 09'th Sep 2024
Summit Therapeutics said its Ivonescimab treatment reduced the risk of disease progression or death by 49% compared with the market leader.
